

Mouse IL-1Ra Immunoassay

Catalog Number: EA800110

For the quantitative determination of mouse IL-1Ra concentrations in cell culture supernates, serum, and plasma.

For research use only. Not for use in diagnostic procedures.

MANUFACTURED AND DISTRIBUTED BY:

OriGene Technologies, Inc.

9620 Medical Center Drive Suite 200 Rockville, MD 20850,USA



TABLE OF CONTENTS

SECTION	PAGE
BACKGROUND	1
PRINCIPLE OF THE ASSAY	1
TECHNICAL HINTS AND LIMITATIONS	2
PRECAUTIONS	2
KIT COMPONENTS& STORAGE CONDITION	IS3
OTHER SUPPLIES REQUIRED BUT NOT SUP	PLIED4
SPECIMEN COLLECTION & STORAGE	4
REAGENTS PREPARATION	4
ASSAY PROCEDURE	6
CALCULATION OF RESULTS	6
PERFORMANCE CHARACTERISTICS	
REFERENCES	




BACKGROUND

Mouse Interleukin-1 receptor antagonist (IL-1ra) is a 22-25 kDa glycoprotein produced by a variety of cell types that antagonizes IL-1 activity. It is a member of the IL-1 family of proteins that includes IL-1a and IL-1 β . Although there is little amino acid (aa) identity (< 30%) among the three IL-1 family members, all molecules bind to the same receptors, all show a β -trefoil structure. Mouse IL-1ra is synthesized as a 178 aa precursor that contains a 26 aa signal sequence plus a 152 aa mature region. Cells known to secrete IL-1ra include dermal fibroblasts, vascular smooth muscle cells, intestinal columnar epithelium, chondrocytes, macrophages, non-keratinized oral stratified squamous epithelium , mast cells, neutrophils and monocytes, Sertoli

cells, and hepatocytes.

PRINCIPLE OF THE ASSAY

This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for IL-1Ra has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any IL-1Ra present is captured by the coated antibody after incubation. Following extensive washing, a biotin-conjugate antibody specific for IL-1Ra is added to detect the captured IL-1Ra protein in sample. For signal development, horseradish peroxidase (HRP)-conjugated Streptavidin is added, followed by tetramethyl-benzidine (TMB) reagent. Following a wash to remove any unbound combination, and enzyme conjugate is added to the wells. Solution containing sulfuric acid is used to stop color development and the color intensity which is proportional to the quantity of bound protein is measurable at 450nm.



Schematic diagram:

Tel: 1-301-340-3188 Mail: techsupport@origene.com Web: www.origene.com



TECHNICAL HINTS AND LIMITATIONS

- 1. This ELISA should not be used beyond the expiration data on the kit label.
- 2. To avoid cross-contamination, use a fresh reagent reservoir and pipette tips for each step.
- 3. To ensure accurate results, some details, such as technique, plasticware and water sources should be emphasized.
- 4. A thorough and consistent wash technique is essential for proper assay performance.
- 5. A standard curve should be generated for each set of samples assayed.
- 6. It is recommended that all standards and samples be assayed in duplicate.
- 7. Avoid microbial contamination of reagents and buffers. Buffers containing protein should be made under aseptic conditions and be prepared fresh daily.
- 8. In order to ensure the accuracy of the results, the standard curve should be made every time.

PRECAUTIONS

The Stop Solution suggested for use with this kit is an acid solution. Wear protective gloves, clothing, eye, and face protection. Wash hands thoroughly after handling.

KIT COMPONENTS& STORAGE CONDITIONS



PART	SIZE	STORAGEOFOPENED/RECONSTITUTED MATERIAL
Microwell Plate - antibody coated 96-well Microplate (8 wells ×12 strips)	1 plate	Return unused wells to the foil pouch containing the desiccant pack. Reseal along entire edge of the zip-seal. May be stored for up to 1 month at $2 - 8^{\circ}C^{**}$
Standard - lyophilized,10000 pg/ ml upon reconstitution	2 vials	Aliquot and Store at -20°C** for six months
Concentrated Biotin-Conjugated antibody (100X) - 120 ul/vial	1 vial	Store at 2-8°C **for six months
Concentrated Streptavidin-HRP solution(100X) - 120 ul/vial	1 vial	Store at 2-8°C** for six months
Standard /sample Diluent - 16 ml/vial	1 bottle	Store at 2-8°C** for six months
Biotin-ConjugateantibodyDiluent - 16 ml/vial	1 bottle	Store at 2-8°C** for six months
Streptavidin-HRP Diluent - 16 ml/vial	1 bottle	Store at 2-8°C** for six months
Wash Buffer Concentrate (20x) - 30 ml/vial	1 bottle	Store at 2-8°C** for six months
Substrate Solution - 12 ml/vial	1 bottle	Store at 2-8°C** for six months
Stop Solution - 12 ml/vial	1 bottle	Store at 2-8°C** for six months
Plate Cover Seals	4 pieces	

******Provided this is within the expiration date of the kit.

OTHER SUPPLIES REQUIRED BUT NOT SUPPLIED

1. Microplate reader capable of measuring absorbance at 450 nm.



- 2. Pipettes and pipette tips.
- 3. Deionized or distilled water.
- 4. Squirt bottle, manifold dispenser, or automated microplate washer.
- 5. 500 mL graduated cylinder.

SPECIMEN COLLECTION & STORAGE

Cell Culture Supernates - Centrifuge cell culture media at 1000×g to remove debris. Assay immediately or aliquot and store samples at \leq -20 °C. Avoid repeated freeze-thaw cycles.

Serum - Use a serum separator tube (SST) and allow samples to clot for 2 hours at

room temperature or overnight at 2-8°C. Centrifuge approximately for 15 minutes at

1000×g. Assay immediately or aliquot and store samples at \leq -20 °C. Avoid repeated freeze-thaw cycles.


Plasma - Collect plasma using EDTA, heparin, or citrate as an anticoagulant. Centrifuge for 15 minutes at 1000×g within 30 minutes of collection. Assay immediately or aliquot and store samples at \leq -20 °C. Avoid repeated freeze-thaw cycles.

Note: The normal mouse serum or plasma samples are suggested to make a 1:2 dilution.

REAGENTS PREPARATION

- **1. Temperature returning** Bring all kit components and specimen to room temperature (20-25°C) before use.
- 2. Wash Buffer Dilute 30mL of Wash Buffer Concentrate with 570mL of deionized or distilled water to prepare 600mL of Wash Buffer. If crystals have formed in the concentrate Wash Buffer, warm to room temperature and mix gently until the crystals have completely dissolved.
- 3. Standard/Specimen Reconstitute the Standard with 1.0mL of Standard/Sample Diluent. This reconstitution produces a stock solution of 10000 pg/mL. Allow the standard to sit for a minimum of 15 minutes with gentle agitation prior to making dilutions. Pipette 750µL of Standard/Sample Diluent into the 2500pg/mL tube, and add 250µL stock solution of 10000 pg/mL into it to get the high standard of 500pg/mL. Pipette 500µL of Standard/Sample Diluent into the remaining tubes. Use the high standard to produce a 2-fold dilution series (below). Mix each tube thoroughly and change pipette tips between each transfer. The 2500 pg/mL standard serves as the high standard. The Standard/Sample Diluent serves as the zero standard (0 pg/mL).





Preparation of IL-1Ra standard dilutions

*If you do not run out of re-melting standard, store it at -20°C. Diluted standard shall not be reused.


4. Working solution of Biotin-Conjugate anti-mouse IL-1Ra antibody: Make a 1:100 dilution of the concentrated Biotin-Conjugate solution with the Biotin-Conjugate antibody Diluent in a clean plastic tube.

*The working solution should be used within one day after dilution.

5. Working solution of Streptavidin-HRP: Make a 1:100 dilution of the concentrated Streptavidin-HRP solution with the Streptavidin-HRP Diluent in a clean plastic tube.

*The working solution should be used within one day after dilution.

ASSAY PROCEDURE





Add 100µl working solution of Biotin-Conjugate anti-mouse IL-1Ra antibody to each
well, incubate 60 minutes,37°C.Image: Constraint of the solution of Streptavidin-HRP to each well, incubate 30 minutes,37°C.Image: Constraint of the solution of Streptavidin-HRP to each well, incubate 30 minutes,37°C.Image: Constraint of the solution of the solution to each well, incubate 15 minutes,37°C.Image: Constraint of the solution to each well, incubate 15 minutes,37°C.Image: Constraint of the solution to each well. Read at 450nm within 5 minutes.

CALCULATION OF RESULTS


- 1. The standard curve is used to determine the amount of specimens.
- First, average the duplicate readings for each standard, control, and sample. All O.D. values are subtracted by the mean value of blank control before result interpretation.
- 3. Construct a standard curve by reducing the data using computer software capable of generating a four parameter logistic (4-PL) curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on the graph.
- 4. The data may be linearized by plotting the log of the IL-1Ra concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.
- 5. This standard curve is provided for demonstration only. A standard curve should be generated for each set of samples assayed.

Standard(pg/ ml)	OD.	OD.	Average	Corrected
0	0.052	0.053	0.052	
39.05	0.129	0.13	0.129	0.077
78.1	0.254	0.239	0.246	0.194
156.2	0.392	0.402	0.397	0.344

Typical data using the IL-1Ra ELISA



312.5	0.538	0.562	0.550	0.497
625	0.934	0.919	0.926	0.874
1250	1.625	1.651	1.638	1.585
2500	2.864	2.913	2.888	2.836



Representative standard curve for IL-1Ra ELISA.

Performance Characteristics

SENSITIVITY: The minimum detectable dose was 20pg/mL.

SPECIFICITY: This assay recognizes both natural and recombinant mouse IL-1Ra. The factors listed below were prepared at 100ng/ml in Standard /sample Diluent and assayed for cross-reactivity and no significant cross-reactivity or interference was observed.



Factors assayed for cross-reactivity

Recombinant mouse	Recombinant rat	Recombinant human
IFN-y	IL-1β□	IL-1a
IL-1a		IL-1β
IL-1β		IL-1 RII
IL-1 RII		IL-1 R3
IL-1 R4		IL-1 R4
IL-2		IL-1 R6
IL-3		IL-1 R9
IL-4		
IL-5		
IL-6		

REPEATABILITY: The coefficient of variation of both intra-assay and inter-assay were less than 10%.

RECOVERY: The recovery of IL-1Ra spiked to three different levels in four samples throughout the range of the assay in various matrices was evaluated.

Sample Type	Average % of Expected Range (%)	Range (%)
Citrate plasma	90	86-107
Cell culture supernatants	105	96-112

Recovery of IL-1Ra in two matrices

LINEARITY: To assess the linearity of the assay, three samples were spiked with high concentrations of IL-1Ra in various matrices and diluted with the appropriate Sample Diluent to produce samples with values within the dynamic range of the assay. (The plasma samples were initially diluted 1:1)

Dilution ratio Recovery (%)	Bacovery (%)	Citrate plasma	Cell	culture
	Citrate plasma	supernatants		



1:2	Average% of Expected	92	103
	Range (%)	85-106	95-117
1:4	Average% of Expected	93	104
1.4	Range (%)	92-109	97-112
1:8	Average% of Expected	96	97
	Range (%)	84-112	88-108
1.10	Average% of Expected	105	96
1:16	Range (%)	95-113	90-107

REFERENCES

- 1. Arend, W.P. et al. (1998) Annu. Rev. Immunol. 16:27.
- 2.Roux-Lombard, P. (1998) Eur. Cytokine Netw. 9:565.
- 3.Zahedi, K. et al. (1991) J. Immunol. 146:4228.
- 4. Eisenberg, S.P. et al. (1991) Proc. Natl. Acad. Sci. USA 88:5232.
- 5. Barton, J.L. et al. (2000) Eur. J. Immunol. 30:3299.



- 6. Gabay, C. et al. (1997) J. Immunol. 159:5905.
- 7. Eisenberg, S.P. et al. (1990) Nature 343:341.
- 8. Yin, J. and M.P. Murtaugh (1999) GenBank Accession #: Q29056.
- 9. Shin, I.S. and H. Youn (2001) GenBank Accession #: AAK01472.
- 10. Kato, H. et al. (1997) Vet. Immunol. Immunopathol. 56:221.
- 11. Muzio, M. et al. (1995) J. Exp. Med. 182:623.
- 12. Haskill, S. et al. (1991) Proc. Natl. Acad. Sci. USA 88:3681.
- 13. Malyak, M. et al. (1998) J. Immunol. 161:1997.
- 14. Muzio, M. et al. (1999) Eur. J. Immunol. 29:781.
- 15. Cao, H.J. et al. (2003) Am. J. Physiol. Cell Physiol. 284:C1429.
- 16. Lin, S-J. et al. (2003) J. Cell. Biochem. 88:836.
- 17. Daig, R. et al. (2000) Gut 46:350.
- 18. Palmer, G. et al. (2002) Arthritis Res. 4:226.
- 19. Janson, R.W. et al. (1991) J. Immunol. 147:4218.
- 20. Perrier, S. et al. (2002) Clin. Exp. Immunol. 127:53